Recommendation ID
Effectiveness and safety of aluminium hydroxide in adults:- In adults with stage 4 or 5 chronic kidney disease (CKD), including those on dialysis, what is the long-term effectiveness and safety of aluminium hydroxide in controlling serum phosphate?
Any explanatory notes
(if applicable)
Why this is important:- Limited evidence was found on the efficacy of aluminium hydroxide in adults and no evidence was found on the long-term efficacy and safety of aluminium hydroxide. A series of RCTs should be conducted separately in adults with stages 4 or 5 chronic kidney disease (CKD) who are not on dialysis and those with stage 5 who are on dialysis. These trials should be run for a minimum of 12 months and should examine the effect of aluminium hydroxide on outcomes such as serum phosphate, serum calcium, adverse events and the ability of the binders to control serum phosphate and calcium within the given ranges. In addition, specific data should be collected on aspects relating to aluminium toxicity.

Source guidance details

Comes from guidance
Chronic kidney disease (stage 4 or 5): management of hyperphosphataemia
Date issued
March 2013

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 27/03/2013